Takeda Sales Force Size For Ramelteon Will Depend On Competitor Detailing

To develop a launch strategy for the insomnia agent, Takeda says it will consider the promotional efforts for Sepracor's Lunesta and for indiplon, which Pfizer and Neurocrine expect to refile with FDA in March/April. Takeda predicts a fall launch for ramelteon.